Sarafotoxin S6c
Need Assistance?
  • US & Canada:
    +
  • UK: +

Sarafotoxin S6c

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Sarafotoxin S6c is a highly selective ETB endothelin receptor agonist (Ki = 0.29 and 28000 nM at ETB and ETA receptors, respectively).

Category
Peptide Inhibitors
Catalog number
BAT-015198
CAS number
121695-87-2
Molecular Formula
C103H147N27O37S5
Molecular Weight
2515.75
Sarafotoxin S6c
Size Price Stock Quantity
1 mg $729 In stock
IUPAC Name
(3S)-3-[[(2S)-5-amino-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16S,19S,22S,25R,28S,31R,36R,39S,42S,45S)-31-amino-22,42-bis(2-amino-2-oxoethyl)-39-benzyl-4,7-bis(2-carboxyethyl)-10,19-bis(carboxymethyl)-13,28-bis[(1R)-1-hydroxyethyl]-45-(2-methylpropyl)-16-(2-methylsulfanylethyl)-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
Synonyms
Sarafotoxin C; S6C; H-Cys-Thr-Cys-Asn-Asp-Met-Thr-Asp-Glu-Glu-Cys-Leu-Asn-Phe-Cys-His-Gln-Asp-Val-Ile-Trp-OH (Disulfide bridge: Cys1-Cys15, Cys3-Cys11); L-cysteinyl-L-threonyl-L-cysteinyl-L-asparagyl-L-alpha-aspartyl-L-methionyl-L-threonyl-L-alpha-aspartyl-L-alpha-glutamyl-L-alpha-glutamyl-L-cysteinyl-L-leucyl-L-asparagyl-L-phenylalanyl-L-cysteinyl-L-histidyl-L-glutaminyl-L-alpha-aspartyl-L-valyl-L-isoleucyl-L-tryptophan (1->15),(3->11)-bis(disulfide)
Appearance
White Solid
Purity
≥95% by HPLC
Density
1.3±0.1 g/cm3
Boiling Point
2679.3±65.0°C at 760 mmHg
Sequence
CTCNDMTDEECLNFCHQDVIW (Disulfide bridge: Cys1-Cys15, Cys3-Cys11)
Storage
Store at -20°C
Solubility
Soluble in Acetonitrile, Water
Application
Vasoconstrictor Agents
InChI
InChI=1S/C103H147N27O37S5/c1-10-46(6)80(100(163)123-67(103(166)167)30-50-37-109-54-19-15-14-18-52(50)54)128-99(162)79(45(4)5)127-95(158)66(36-78(144)145)120-85(148)55(20-23-71(105)133)112-90(153)61(31-51-38-108-43-110-51)117-97(160)69-40-170-169-39-53(104)83(146)129-81(47(7)131)102(165)126-70-42-172-171-41-68(96(159)115-59(28-44(2)3)88(151)118-62(32-72(106)134)91(154)116-60(89(152)125-69)29-49-16-12-11-13-17-49)124-86(149)57(22-25-75(138)139)111-84(147)56(21-24-74(136)137)113-94(157)65(35-77(142)143)122-101(164)82(48(8)132)130-87(150)58(26-27-168-9)114-93(156)64(34-76(140)141)121-92(155)63(33-73(107)135)119-98(70)161/h11-19,37-38,43-48,53,55-70,79-82,109,131-132H,10,20-36,39-42,104H2,1-9H3,(H2,105,133)(H2,106,134)(H2,107,135)(H,108,110)(H,111,147)(H,112,153)(H,113,157)(H,114,156)(H,115,159)(H,116,154)(H,117,160)(H,118,151)(H,119,161)(H,120,148)(H,121,155)(H,122,164)(H,123,163)(H,124,149)(H,125,152)(H,126,165)(H,127,158)(H,128,162)(H,129,146)(H,130,150)(H,136,137)(H,138,139)(H,140,141)(H,142,143)(H,144,145)(H,166,167)/t46-,47+,48+,53-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,79-,80-,81-,82-/m0/s1
InChI Key
LXPHPKVWHQLBBA-JHOSIGDNSA-N
Canonical SMILES
CCC(C)C(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CNC=N3)NC(=O)C4CSSCC(C(=O)NC(C(=O)NC5CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)CC6=CC=CC=C6)CC(=O)N)CC(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC5=O)CC(=O)N)CC(=O)O)CCSC)C(C)O)CC(=O)O)CCC(=O)O)CCC(=O)O)C(C)O)N
1. Endothelin
P Braquet, P E Chabrier Horm Res . 1990;34(3-4):169-74. doi: 10.1159/000181819.
Endothelin (ET) belongs to a family of 21 amino acid peptides comprising at least three isoforms in man. Originally identified as an endothelium-derived vasoconstrictive substance, ET arises from a precursor peptide which is cleaved and released by a specific ET-converting enzyme. ET exerts multiple pharmacological effects through its own receptors. Among them, ET evokes the sustained and poorly reversible contraction of isolated vascular preparations and induces in vivo a long-lasting pressor effect preceded by transient hypotension. The mechanism of action of ET is not yet clarified although ET has been shown to stimulate phospholipase C and protein kinase C. It seems probable that this peptide acts more as a paracrine or autocrine signal than a circulating hormone. The availability of specific receptor antagonists and inhibitors of its biosynthesis will allow to understand the biological relevance of this novel family of peptides.
2. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes
K L Jones, B V Clineschmidt, E V Lis, D J Pettibone, D L Williams Jr Biochem Biophys Res Commun . 1991 Mar 15;175(2):556-61. doi: 10.1016/0006-291x(91)91601-8.
In contrast to endothelin-1 (ET-1) and several of its analogues, sarafotoxin S6c (S6c) was a much more potent inhibitor of [125I]-ET-1 binding in rat hippocampus and cerebellum (Ki approximately 20 pM) than in rat atria and aorta (Ki approximately 4500 nM), suggesting the existence of ET-1 receptor subtypes (aorta/atria, ETA; hippocampus/cerebellum, ETB). S6c was a potent activator of PI turnover in hippocampus (EC50 approximately 10 nM) but not atria (EC50 greater than 1 microM), unlike ET-1 which was active in both tissues. S6c, therefore, is a highly selective ETB agonist. Furthermore, S6c was a potent pressor agent in the pithed rat (ED25 mm Hg approximately 0.1 nmoles/kg, i.v.), suggesting that the ETB receptor subtype may be important in cardiovascular function.
3. Distinct endothelin-B receptors mediate the effects of sarafotoxin S6c and IRL1620 in the ileum
N Miasiro, H Karaki, A C Paiva J Cardiovasc Pharmacol . 1998;31 Suppl 1:S175-8. doi: 10.1097/00005344-199800001-00050.
In the guinea pig ileum, both sarafotoxin S6c (S6c) and IRL1620 induced a biphasic effect (relaxation and contraction). S6c induced strong tachyphylaxis of both components of the response, but IRL1620 induced tachyphylaxis mainly of the contractile component. Whereas the tissues rendered tachyphylactic to S6c did not respond to IRL1620, a normal biphasic response to S6c was observed in the tissues rendered tachyphylactic to IRL1620. In the presence of IRL1620, S6c could induce its biphasic effect, whereas in the presence of S6c, IRL1620 was ineffective. BQ-123, a specific ETA antagonist, did not affect the biphasic response induced by either agonist. PD145065, a potent ETA/ETB antagonist, was a competitive and a noncompetitive antagonist, respectively, of the contractile components of IRL1620 and S6c. RES-701-1, a specific ETB1 antagonist, inhibited both components of the response induced by IRL1620. However, it inhibited mainly the relaxant component induced by low doses of S6c. Apamin had different effects on endothelin-1 (ET-1), S6c, and IRL1620. Our results suggest that there are at least two distinct populations of ETB receptors mediating the biphasic response: the ETB1 receptor, sensitive to RES-701-1 and PD145065, and the ETB2 receptor, less sensitive to RES-701-1 and PD145065.
Online Inquiry
Verification code
Inquiry Basket